Hyperspectral Imaging Sensor Patent Landscape 2026
Hyperspectral Imaging Sensor Patent Landscape in 2026
The hyperspectral imaging sensor field spans 2,123 patent families and is led by SD Sight Diagnostics, with the top five filers holding a moderate 20% share of the hundred largest filers’ combined output, indicating a competitive but not yet consolidated field. Activity peaked in 2020 and has plateaued at a high level, with the United States as the dominant filing jurisdiction and material analysis as the dominant technology branch.
SD Sight Diagnostics leads a moderately concentrated field
SD Sight Diagnostics holds the top position with 107 patent families, nearly double the second-ranked Leica Microsystems CMS GmbH at 56, establishing a clear leader ahead of a dense chasing pack.
The top five filers — SD Sight Diagnostics, Leica Microsystems CMS GmbH, OutSense Diagnostics, Ethicon, and Panasonic Intellectual Property Management — account for 20% of the hundred largest filers’ combined total, a moderate concentration level that leaves meaningful room for challengers and new entrants.
| # | Applicant | Patent families | Share |
|---|---|---|---|
| 1 | SD Sight Diagnostics Ltd | 107 | |
| 2 | Leica Microsystems CMS GmbH | 56 | |
| 3 | OutSense Diagnostics Ltd | 52 | |
| 4 | Ethicon Inc. | 49 | |
| 5 | Panasonic Intellectual Property Management Co., Ltd. | 48 | |
| 6 | Canon Inc. | 47 | |
| 7 | Cilag GmbH International | 45 | |
| 8 | Leica Instruments (Singapore) Pte Ltd | 42 | |
| 9 | ArcelorMittal SA | 40 | |
| 10 | The Boeing Company | 35 |
| # | Applicant | Patent families | Share |
|---|---|---|---|
| 11 | Clarapath Inc. | 35 | |
| 12 | COMMONWEALTH SCI & IND RES ORG | 31 | |
| 13 | Altria Client Services LLC | 30 | |
| 14 | Agri Advanced Technologies GmbH | 30 | |
| 15 | BASF Coatings GmbH | 27 | |
| 16 | Leica Geosystems AG | 26 | |
| 17 | imec | 23 | |
| 18 | Agnetix Inc. | 22 | |
| 19 | Plotlogic Pty Ltd | 22 | |
| 20 | TOMRA Sorting NV | 21 |
The leaders’ portfolios span diagnostics, microscopy, and industrial inspection, suggesting the sensor technology is being pulled into multiple end-markets simultaneously rather than converging on a single dominant application.
Filing counts for 2025 and 2026 are materially under-reported due to standard patent publication lag and should not be read as a decline in activity. Longer-window growth, applicant concentration, and technology-route coverage are therefore more reliable signals than the latest-year bar alone.
A 2020 peak followed by a high-volume plateau; material analysis dominates the technology mix
The filing trend reveals a field that surged to a 2020 peak of 320 families per year and has since plateaued at an elevated level, while the technology composition chart shows material analysis as the dominant class with several applied-AI and clinical branches growing in relative weight.
Annual filing trend
Annual filings rose sharply from 177 in 2017 to a peak of 320 in 2020, then stabilised in the 260–290 range through 2022–2023 before recorded counts begin declining — a pattern consistent with publication lag rather than a real retreat. The field is best characterised as past-peak on an annual basis but still at a historically high volume.
↗ Hover for values · click a bar to ask EurekaTechnology composition
G01N (material analysis and testing) is the dominant branch by a wide margin, reflecting the sensor’s core spectrochemical identity. Secondary branches — G01J (radiation and light measurement), G06T (image data processing), A61B (diagnosis and surgery), and G01S (radar, sonar and positioning) — show that the technology is being integrated with image-AI pipelines and clinical diagnostic workflows at meaningful but lower scale.
↗ Hover for values · click a bar to ask EurekaHighly cited patent families surfaced by the query
Citation-heavy patent families returned by the query. Use this section as citation context, not as a curated list of the most topic-specific patents.
Hyperspectral imaging sensor
Systems, methods, and computer readable media for hyperspectral imaging are provided. An example hyperspectral imaging sensor system to identify item composition includes an imager to capture hyperspectral imaging data of one or more items with respect to a target. The example includes a sensor to be positioned with respect to the target to trigger capture… (excerpt from the patent abstract)
| # | Patent | Citations |
|---|---|---|
| 1 | Method for automatic phenotype measurement and se… | 310 |
| 2 | Systems, Methods and Devices for Collecting Data a… | 294 |
| 3 | Combined spectral and polarimetry imaging and diag… | 221 |
| 4 | Automated threat detection and deterrence apparatus | 210 |
| 5 | System for Multi- and Hyperspectral Imaging | 128 |
| 6 | Robotic surgical systems with mechanisms for scali… | 122 |
| 7 | Apparatuses and methods for BIO-sensing using unma… | 121 |
| 8 | Methods and systems for tracking and guiding senso… | 115 |
Ranked by total forward citations. Citation counts favour older and broadly cited patent families, and broad or adjacent patents may appear when they match the search scope. Treat this section as citation context, not as a curated list of the most topic-specific patents. Some patent titles may be shown in their original, non-English language where an accurate translation could not be guaranteed.
What the patent structure means for R&D investment decisions
The combination of a maturing filing pace, moderate concentration, active new entrants, and a broad multi-sector technology mix creates a nuanced investment environment where focus and speed of IP execution matter more than raw volume.
Field is at a high-volume plateau following a 2020 peak
Annual filings peaked at 320 families in 2020 and have since plateaued near that level, placing the field in a mature phase where foundational IP positions are largely staked. New entrants will need to target sub-domains or adjacent branches to find defensible whitespace rather than competing head-on in well-covered core claims.
Maturity · plateauModerate concentration with a pronounced leader gap
The top five filers hold 20% of the hundred largest filers’ combined output, a moderate share that leaves the majority of activity distributed across a large number of applicants. The gap between SD Sight Diagnostics (107 families) and the second-ranked Leica Microsystems CMS GmbH (56 families) is large enough that short-term displacement of the leader would require sustained and focused filing activity.
Concentration · moderateLeica Microsystems and Leica Instruments (Singapore) are the most active co-filers
The only co-applicant relationship identified in the evidence is between Leica Microsystems CMS GmbH and Leica Instruments (Singapore) Pte Ltd, with 18 jointly filed families — a corporate-entity collaboration within the Leica group rather than an external partnership. The broader ecosystem shows limited cross-organisational co-filing, suggesting most players are building proprietary portfolios independently.
Collaboration · limitedUnited States is the primary filing jurisdiction; Europe and PCT follow
The United States leads with 833 patent records, followed by Europe (EPO) at 421 and WIPO (PCT) at 316. China ranks fourth at 251 records, while India and Australia show emerging filing activity. The relatively lower count in Japan (22 records) and South Korea (45 records) compared to their usual technology-sector presence may indicate addressable gaps in Asian market coverage.
Geography · US-ledGo beyond the landscape: Eureka’s TRIZ Solution agent breaks down an R&D problem and returns patented concept solutions, each with a technical approach and cited patent & literature evidence.
| Applicant | Collaborator | Co-filings |
|---|---|---|
| Leica Microsystems CMS GmbH | Leica Instruments (Singapore) Pte Ltd | 18 |
Co-filing pairs, ranked by the number of jointly-filed patent families.
SD Sight Diagnostics dominates diagnostics; Leica Microsystems is a fast-rising challenger
The two leading applicants occupy distinct technology positions — one anchored in blood diagnostics and material analysis, the other in microscopy and optical systems — meaning their IP portfolios are largely complementary rather than directly competitive.
SD Sight Diagnostics
SD Sight Diagnostics holds 107 patent families, concentrating its portfolio in material analysis (G01N 21 and G01N 33) and particle characterisation (G01N 15), consistent with its blood-cell diagnostics core business. Its applicant momentum shows a sharp recent decline (▼ –60%), suggesting the foundational portfolio is largely complete and new filing activity has slowed.
families: 107Leica Microsystems CMS GmbH
Leica Microsystems CMS GmbH ranks second with 56 patent families, focused on material analysis (G01N 21, G01N 33) and optical microscopy systems (G02B 21). Its momentum trend is classified as a new entrant (▲ new entrant) in the recent window, indicating rapid portfolio build-up. The Leica group’s intra-corporate co-filing relationship with Leica Instruments (Singapore) adds 18 joint families to the combined position.
families: 56| Applicant | Recent (3 yrs) | Trend |
|---|---|---|
| SD Sight Diagnostics Ltd | 21 | ▼ -60% |
| Leica Microsystems CMS GmbH | 47 | ▲ new entrant |
| OutSense Diagnostics Ltd | 8 | ▲ new entrant |
| Panasonic Intellectual Property Management Co., Ltd. | 29 | ▲ +142% |
| Canon Inc. | 6 | ▼ -84% |
| Leica Instruments (Singapore) Pte Ltd | 29 | ▲ new entrant |
| The Boeing Company | 3 | ▲ new entrant |
| Clarapath Inc. | 8 | ▼ -68% |
Under-served branches in image-AI integration and radar-fusion positioning
While material analysis (G01N) dominates the corpus, several adjacent branches with plausible technical synergies show relatively low patent density, pointing to areas where incremental differentiation may be achievable.
G06T · Image data processing and generation
This branch accounts for 416 patent records — a 6% share — compared to the dominant G01N branch. Hyperspectral data volumes create a strong need for specialised compression, reconstruction, and real-time processing algorithms, yet the patent density here remains relatively sparse. Entry paths include learned spectral unmixing, on-sensor AI inference, and edge-compute architectures tailored to hyperspectral data cubes.
Search this in Eureka →G01S · Radar, sonar and positioning (sensor fusion)
G01S covers 330 patent records at a 5% share, indicating limited but growing activity in fusing hyperspectral imaging with ranging and positioning modalities. Airborne and UAV platforms increasingly combine LiDAR or radar with hyperspectral cameras for precision agriculture, mineral mapping, and defence applications; the sparse IP density here suggests room for differentiated sensor-fusion architectures and calibration methods.
Search this in Eureka →How leading applicants differ across technology routes
Strength of each leader across the main technology routes.
| Player | G01N 21 · Material analysis & testing | G01N 33 · Material analysis & testing | G01J 3 · Radiation & light measurement | G06T 7 · Image data processing & generation | G01S 17 · Radar, sonar & positioning |
|---|---|---|---|---|---|
| Ethicon Inc. | Strong · 43 | Absent | Moderate · 16 | Moderate · 18 | Strong · 52 |
| OutSense Diagnostics Ltd | Strong · 46 | Strong · 30 | Moderate · 23 | Moderate · 11 | Absent |
| SD Sight Diagnostics Ltd | Strong · 53 | Strong · 53 | Absent | Absent | Absent |
| Altria Client Services LLC | Strong · 30 | Absent | Strong · 30 | Strong · 26 | Absent |
| Canon Inc. | Strong · 42 | Absent | Strong · 24 | Absent | Absent |
| Leica Microsystems CMS GmbH | Strong · 34 | Strong · 21 | Absent | Moderate · 10 | Absent |
| Panasonic Intellectual Property Management Co., Ltd. | Strong · 25 | Absent | Strong · 29 | Absent | Moderate · 6 |
Frequently asked questions
The corpus covers 2,123 patent families globally, representing the broadest measure of proprietary R&D activity in this technology as captured in the evidence.
SD Sight Diagnostics Ltd holds the top position with 107 patent families, focused on material analysis and blood-cell diagnostics applications. Leica Microsystems CMS GmbH ranks second with 56 families.
Annual filings peaked at 320 families in 2020 and have since plateaued at an elevated level, placing the field in a mature phase rather than an active growth phase. The most recent years (2025–2026) appear lower due to standard patent publication lag and do not represent a real decline.
The United States leads with 833 patent records, followed by Europe (EPO) at 421, WIPO (PCT) at 316, and China at 251. India and Australia show emerging activity, while Japan and South Korea are relatively under-represented given their technology-sector scale.
G01N (material analysis and testing) is the dominant branch by a wide margin. Secondary branches include G01J (radiation and light measurement), G06T (image data processing), A61B (diagnosis and surgery), and G01S (radar, sonar and positioning), reflecting diverse end-market applications.
G06T (image data processing and generation) at a 6% branch share and G01S (radar, sonar and positioning) at a 5% share are the two relatively sparse branches with clear technical synergy to hyperspectral sensors — particularly in on-sensor AI inference and sensor-fusion architectures for airborne platforms.
Ready to map your own hyperspectral imaging landscape?
Join 18,000+ innovators using PatSnap Eureka to map any technology landscape: search 2B+ patents and papers, surface key assignees, and generate a report like this in minutes.
Disclaimer. This page is generated from PatSnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. PatSnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.